Sugi Predict

Sugi Predict / Compounds / SCHEMBL657691

SCHEMBL657691

SCHEMBL657691

O=C(C=Cc1ccccc1)c1c[nH]c2ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 1.00
▸ RAB9A P51151 3/20 1.00
▸ TDP1 Q9NUW8 1/20 1.00
▸ MAOB P27338 1/20 0.79
▸ GPR84 Q9NQS5 1/20 0.57
▸ MAPT P10636 5/20 0.56
▸ ALDH1A1 P00352 3/20 0.56
▸ MEN1 O00255 3/20 0.56
▸ KMT2A Q03164 3/20 0.56
▸ HPGD P15428 2/20 0.56
▸ NFKB1 P19838 1/20 0.56
▸ NFKB2 Q00653 1/20 0.56
▸ RELA Q04206 1/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ LMNA P02545 2/20 0.55
▸ KDM4E B2RXH2 1/20 0.55
▸ TP53 P04637 1/20 0.55
▸ MAPK1 P28482 1/20 0.55
▸ PBRM1 Q86U86 1/20 0.54
▸ ATM Q13315 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29522745 1.00 NPC1 (1.00) NPC1RAB9ATDP1MAOBGPR84
SCHEMBL657690 1.00 NPC1 (1.00) NPC1RAB9ATDP1MAOBGPR84
SCHEMBL8960003 0.85 NPC1 (0.73) NPC1RAB9ATDP1MAOBMAPT
SCHEMBL8959997 0.85 NPC1 (0.73) NPC1RAB9ATDP1MAOBMAPT
SCHEMBL27984170 0.84 NPC1 (0.72) NPC1RAB9ATDP1MAOBGPR84
SCHEMBL6495175 0.84 NPC1 (0.72) NPC1RAB9ATDP1MAOBGPR84
SCHEMBL6495182 0.84 NPC1 (0.72) NPC1RAB9ATDP1MAOBGPR84
SCHEMBL8959963 0.82 NPC1 (0.68) NPC1RAB9ATDP1MAOBGPR84
SCHEMBL8959956 0.82 NPC1 (0.68) NPC1RAB9ATDP1MAOBGPR84
SCHEMBL31745446 0.79 NPC1 (0.65) NPC1RAB9ATDP1MAOBGPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210008070-A1 TARGETING MINIMAL RESIDUAL DISEASE IN CANCER WITH CD36 ANTAGONISTS KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2021-01-14 — — US claimed
EP-3752187-A1 TARGETING MINIMAL RESIDUAL DISEASE IN CANCER WITH CD36 ANTAGONISTS VIB vzw (BE) 2020-12-23 — — EP claimed
WO-2019158581-A1 TARGETING MINIMAL RESIDUAL DISEASE IN CANCER WITH CD36 ANTAGONISTS VIB VZW (BE) 2019-08-22 — — WO claimed
US-20150259429-A1 CLUSTER OF DIFFERENTIATION 36 (CD36) AS A THERAPEUTIC TARGET FOR HIV INFECTION INSTITUT CURIE (FR) 2015-09-17 — — US claimed
EP-2890713-A1 CLUSTER OF DIFFERENTIATION 36 (CD36) AS A THERAPEUTIC TARGET FOR HIV INFECTION Institut Curie (FR) 2015-07-08 — — EP claimed
WO-2014033130-A1 CLUSTER OF DIFFERENTIATION 36 (CD36) AS A THERAPEUTIC TARGET FOR HIV INFECTION INSTITUT CURIE (FR) 2014-03-06 — — WO claimed
US-20130116308-A1 CD36 INHIBITION TO CONTROL OBESITY AND INSULIN SENSITIVITY CORNELL UNIVERSITY (US) 2013-05-09 — — US claimed
CN-103037901-A Cd36 inhibition to control obesity and insulin sensitivity UNIV CORNELL 2013-04-10 — — CN claimed
WO-2011153209-A2 CD36 INHIBITION TO CONTROL OBESITY AND INSULIN SENSITIVITY CORNELL UNIVERSITY (US) 2011-12-08 — — WO claimed
US-20260034071-A1 HIGH-PURITY PEG LIPIDS AND USES THEREOF MODERNATX, INC. (US) 2026-02-05 — — US disclosed
US-12383508-B2 High-purity peg lipids and uses thereof MODERNATX, INC. (US) 2025-08-12 — — US disclosed
EP-3752644-B1 TUMOR MINIMAL RESIDUAL DISEASE STRATIFICATION VIB VZW (BE) 2025-07-16 — — EP disclosed
US-20250152518-A1 PEG LIPIDS AND USES THEREOF MODERNATX, INC. (US) 2025-05-15 — — US disclosed
US-12151029-B2 PEG lipids and uses thereof MODERNATX, INC. (US) 2024-11-26 — — US disclosed
EP-2349999-A1 ALLOSTERIC PROTEIN KINASE MODULATORS Universität des Saarlandes (DE) 2011-08-03 — — EP disclosed
WO-2010043711-A1 ALLOSTERIC PROTEIN KINASE MODULATORS UNIVERSITAET DES SAARLANDES (DE) 2010-04-22 — — WO disclosed
EP-2177510-A1 Allosteric protein kinase modulators Universität des Saarlandes (DE) 2010-04-21 — — EP disclosed
US-5530019-A FOR TREATMENT OF PROSTATE GLAND DISORDERS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-06-25 — — US disclosed
EP-0648208-A1 INDOLE DERIVATIVES AS TESTOSTERONE 5 ALPHA-REDUCTASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1995-04-19 — — EP disclosed
WO-1994022821-A1 INDOLE DERIVATIVES AS TESTOSTERONE 5 ALPHA-REDUCTASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1994-10-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250152518-A1 PEG LIPIDS AND USES THEREOF LIPA, LIPG, LIPC NPC1 78/4885RAB9A 457/4885TDP1 3574/4885
US-20260034071-A1 HIGH-PURITY PEG LIPIDS AND USES THEREOF LNPEP, AUP1, PLTP NPC1 168/4885RAB9A 667/4885TDP1 3569/4885
US-20130116308-A1 CD36 INHIBITION TO CONTROL OBESITY AND INSULIN SENSITIVITY GPR119, IRS1, INSR NPC1 513/4885RAB9A 1364/4885TDP1 4759/4885
US-12151029-B2 PEG lipids and uses thereof LIPA, LIPG, LNPEP NPC1 95/4885RAB9A 506/4885TDP1 3598/4885
US-12383508-B2 High-purity peg lipids and uses thereof LIPA, HDLBP, PLTP NPC1 50/4885RAB9A 182/4885TDP1 4385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.